Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low -
risk myelodysplastic syndromes.
Inclusion Criteria: • Pathologically proven acute myeloid leukemia (AML) or intermediate, high - risk, or very high
risk Myelodysplastic Syndrome (MDS) as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS - R) which is relapsed or refractory (R / R) to standard therapy and / or for which standard therapy is contraindicated or which has not adequately responded to standard therapy.
Not exact matches
It is approved for treating low -
risk, transfusion - dependent
myelodysplastic syndrome (MDS) patients with an abnormality of chromosome 5q.
Emergence and evolution of TP53 mutations are key features of disease progression in
myelodysplastic patients with lower -
risk del (5q) treated with lenalidomide
Children with SDS have a higher than normal
risk of developing blood disorders like
myelodysplastic syndrome (MDS) and leukemia.